Picking through the scraps. Following the bankruptcy of 'digital pill' maker Proteus Digital Health, business partner and stakeholder Otsuka Pharmaceutical has been approved to purchase the digital health company's assets by a federal bankruptcy court judge, STAT reports.
Otsuka's bid was challenged by Novartis, two former Proteus executives and other investors, who argued that the agreed upon $...
In the newest episode of HIMSSCast, MobiHealthNews founding editor Brian Dolan, now founder and lead writer at Exits and Outcomes, joins the host, Jonah Comstock, Managing Editor Laura Lovett and Associate Editor Dave Muoio for a bit of a post-mortem on Proteus Digital Health, the sensor-enabled pill company that filed for Chapter 11 bankruptcy protection last week.
More related to this...
Proteus Digital Health, maker of an ingestible sensor for tracking medication adherence, filed for Chapter 11 bankruptcy protection yesterday.
The news comes months after word that the company had furloughed much of its staff, reassessed its high-profile partnership with Otsuka Pharmaceutical and shifted away from its primary focus area of mental disorder treatment.
The "smart pill" maker...
Following news of hardships at Proteus Digital Health, CEO Andrew Thompson has told STAT News that the company is winding down its high-profile $88 million deal with Otsuka Pharmaceutical, and will be pivoting from its current primary focus on mental disorders toward cancers and infectious disease treatments.
The pharmaceutical company has now acquired the full license for Proteus’ mental health...
It has been a tumultuous week in the realm of digital health partnerships. It started with word of Proteus Digital Health’s floundering business and failed investment round, which reports say was partially driven by cooling relations between the digital pill maker and its longtime patron Otsuka Pharmaceuticals. A few days later, Sanofi announced a company-wide strategy shift that found Onduo, its...
Gainesville, Florida-based etectRx has received FDA 510(k) clearance for its ID-Cap System, a prescription ingestible system that sends adherence event logs to an external medical device.
Similar to the system pioneered by etectRx’s high-profile competitor, Proteus Digital Health, the ID-Cap’s core is a standard capsule containing a sensor that transmits a message once it comes into contact with...
Proteus Digital Health, maker of an ingestible sensor system for treatment adherence monitoring, was forced to furlough many of its employees last month after a $100 million funding round didn’t close as expected, according to a weekend report from CNBC.
These employees were brought back after about two weeks after Proteus was able to secure $5 million in emergency funding, according to the...
A new study suggests that Proteus Digital Health’s sensor-embedded pills can improve adherence among Hepatitis C (HCV) patients who are at a high risk for nonadherence.
The data — presented this week at the American Association for the Study of Liver Diseases’ (AASLD) The Liver Meeting — indicate a 93% overall rate of medication adherence, and a 99.5% rate of sustained virologic response recorded...
Proteus Digital Health’s ingestible pill and sensor system could improve medication adherence, and subsequently treatment, for patients with tuberculosis (TB), according to new data from an independent study conducted in California.
Published Friday in PLoS Medicine, the trial found Proteus’ system to accurately determine whether or not a medication was taken. Patients using the system at home...
In conjunction with Fairview Health Services and University of Minnesota Health, Proteus Digital Health unveiled plans to pair its sensor-equipped digital pills with an oral oncology therapeutic.
According to an announcement from Proteus, the new care model is currently being used to treat stage 3 and stage 4 colorectal cancer patients receiving care at Fairview. There, clinicians are prescribing...
